Seront, Emmanuel http://orcid.org/0000-0003-4807-7472
Froidure, Antoine http://orcid.org/0000-0001-7133-1788
Revencu, Nicole http://orcid.org/0000-0002-7120-4903
Dekeuleneer, Valerie http://orcid.org/0000-0003-1210-6112
Clapuyt, Philippe http://orcid.org/0000-0001-6942-765X
Dumitriu, Dana http://orcid.org/0000-0003-0749-9695
Vikkula, Miikka http://orcid.org/0000-0002-6236-338X
Boon, Laurence M. http://orcid.org/0000-0001-8273-3328
Article History
Received: 20 April 2024
Accepted: 5 May 2024
First Online: 16 May 2024
Declarations
:
: The patient and his parent were provided with comprehensive information regarding sirolimus as outlined in the VASE trial protocol. They consented to participate in the trial by signing the informed consent forms. Additionally, the patient consented to receive detailed information about trametinib, either as a standalone treatment or in combination with sirolimus, before signing another informed consent form. The patient's treatment and follow-up were conducted in accordance with the CARE guidelines.
: Even if images are entirely unidentifiable, written inform consents from the patient and his parents were obtained for publication.
: The authors declare no competing interests.